Heart Disease
Amarin Corporation Announces First Patients Enrolled In Two Phase 3 Clinical Trials Assessing AMR101 for the Treatment of Cardiovascular Disease
Published in Obesity and Diabetes Week, January 18th, 2010
Amarin Corporation plc (NASDAQ:AMRN), a clinical-stage biopharmaceutical company focused on improving the treatment of cardiovascular disease, announced that first patients were enrolled in the MARINE and ANCHOR Phase 3 clinical trials for AMR101, the Company's lead product candidate. These clinical trials are designed to demonstrate that AMR101 lowers triglyceride levels in patients with very high triglycerides (the MARINE Study) and high triglycerides in patients with mixed dyslipidemia being treated with statins (the ANCHOR Study). It is estimated that over 27 million people in the US have elevated triglyceride levels which are associated with the increased risk of developing coronary...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
More Articles from Obesity and Diabetes Week
- Elsevier Health Sciences
Restaurant and packaged foods can have more calories than nutrition labeling indicates - JAMA and Archives Journals
Metabolic risks remain largely unmonitored in Medicaid patients taking antipsychotics - Jessica Jonap Public Relations
Incidence of type 1 diabetes doubles in 20 years, continues rising at 3 percent per year -- but why? - Mayo Clinic
Mayo researchers find obesity key - Research
Leptin-controlled gene can reverse diabetes - University of Iowa
Study provides insight into pathway linked to obesity - More from this issue of Obesity and Diabetes Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
